Goldman Sachs initiates Royalty Pharma stock with Buy rating, $42 target

Goldman Sachs initiated coverage on Royalty Pharma (RPRX) with a Buy rating and a $42 price target, projecting an 8.7% CAGR in royalty receipts to $4.6 billion by 2030, driven by its unique exposure to stable biopharma royalty streams and ongoing portfolio expansion. The firm highlighted RPRX's low beta (0.57) and strong financial health, valuing it at an 11x EV/EBITDA multiple. This follows RPRX's recent $885 million acquisition of a royalty interest in Amgen's Imdelltra, with UBS maintaining a Neutral rating at a $38 target, contrasting with TD Cowen's reiterated Buy at $42.

Analysis

Goldman Sachs has initiated coverage on Royalty Pharma (RPRX) with a 'Buy' rating and a $42.00 price target, signaling approximately 20% upside from current levels. The core of the bull thesis rests on RPRX's unique model providing stable exposure to biopharma royalty streams, which is supported by the stock's low beta of 0.57 and a 'GREAT' financial health score from InvestingPro. Goldman projects an 8.7% compound annual growth rate (CAGR) in royalty receipts to $4.6 billion by 2030, a figure that surpasses the consensus estimate of $4.3 billion. The firm's $42 target is derived from an 11x EV/EBITDA multiple, aligning RPRX with higher-growth pharmaceutical peers. This positive outlook is substantiated by recent strategic actions, including an $885 million upfront payment for a royalty interest in Amgen's Imdelltra. However, analyst sentiment is not uniformly bullish; while TD Cowen also holds a 'Buy' rating at $42, UBS maintains a 'Neutral' stance with a $38 target, citing unspecified 'perceived structural issues,' even as the stock trades near its 52-week high after a 40% year-to-date gain.

Key Decisions for Investors

• Investors may view the Goldman Sachs 'Buy' initiation, with its above-consensus growth forecast of an 8.7% CAGR, as a compelling rationale to build or add to a position in RPRX.
• Given the stock's 40% year-to-date appreciation and a 'Neutral' rating from UBS citing 'structural issues,' it is prudent to weigh the upside potential against the risk that the stock is already fairly valued near its 52-week high.
• Monitor the company's execution on its portfolio expansion strategy, such as the recent Imdelltra royalty acquisition, as this is a key driver of the bull thesis and its valuation relative to the 10-14x EV/EBITDA peer group range.